Establishment Labs Announces the Appointment of Dr. David Hung to Its Board of Directors

Establishment Labs is pleased to announce the appointment of Dr. David Hung to the company´s Board of Directors.
“We are honored to welcome David to our Board of Directors. He is a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to our company as we expand into new markets and develop innovative products that improve patient outcomes.”
Dr. David Hung is the Founder, President, and CEO of Medivation, a San Francisco-based life sciences company. Dr. Hung first identified and in-licensed enzalutamide, a novel androgen receptor antagonist, in 2005, and led the development of enzalutamide from discovery and preclinical testing to approval for human use as Xtandi. Today, Xtandi is approved for the treatment of metastatic castration resistant prostate cancer in more than 55 countries, with worldwide net sales exceeding $2 billion on an annualised basis.
“Establishment Labs is taking a rigorous approach to innovation in an industry where it is much needed,” said David Hung. "Establishment has already created a product portfolio that I believe will set new standards in the industry, and they are well-positioned to deliver next generation products that will further address unmet medical needs and improve patient outcomes.”
Ed Schutter, Director at Establishment Labs and CEO of Arbor Pharmaceuticals, commented, "We welcome David to the Board of Directors and greatly respect his accomplishments at Medivation developing Xtandi. The talent and knowledge at Establishment Labs is remarkable for this industry, and the cross disciplinary approach will lead to better and safer options across breast reconstruction and aesthetics.”
Prior to Medivation, Dr. Hung was President and CEO of Pro-Duct Health, a venture capital-backed company focused on the early detection of breast cancer. Dr. Hung was the inventor of the Pro-Duct catheter which enabled the detection of early cellular atypia in women at high risk for breast cancer and he led the development of the catheter which resulted in its FDA clearance. Three years after raising a total of $22M in venture funding, the company sold for $168M in 2001 to Cytyc Corporation, one of the world's largest makers of cervical pap smears. Prior to Pro-Duct Health, Dr. Hung was Vice President of Lead Discovery and Development at Chiron Corporation. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, and an A.B. summa cum laude from Harvard University.

Establishment Labs Announces Appointment of Dr. Scott Spear to its Medical Advisory Board

Establishment Labs, a global next generation breast implant and medical technology company, announced today that Dr. Scott L.Spear has joined its Medical Advisory Board.

"We are partnering with the best minds in plastic surgery to bring the latest technological innovations in breast implants to the United States market. The appointment of Dr. Spear is a clear indication of this strategy. We are honored to have a plastic surgeon of his stature joining our Medical Advisory Board," said Juan Jose Chacon Quiros, CEO of Establishment Labs.

“Dr. Spear’s leadership and expertise will be instrumental in working with doctors in the 46 countries where surgeons currently use or are switching to Motiva. With best practices and Motiva next generation technologies, we can improve patient outcomes and vastly reduce complication rates.”

Between 1992 and 2015, Dr. Scott Spear served, at different times, as Director, Chief and Chairman of the Department of Plastic Surgery at the Georgetown University School of Medicine. Dr. Scott Spear is the author of more than 130 peer-reviewed articles in scientific journals and has collaborated on over 200 chapters and 3 books on Plastic and Reconstructive Surgery. Before resigning in December 2015, Dr. Spear also served as the Chairman of the Plastic Surgery Executive Council at Allergan Inc.

Dr. Spear commented, "For some time, I have been thinking about the high rates of some complications associated with breast implants, and how we should endeavor to radically reduce these rates. Establishment Labs shares that goal, and it is a pleasure for me to support their work and help them to continue their culture of innovation.”

“Today, the vast majority of implants sold are based on our 1992 understanding of how the body reacts to breast implants and silicone. Motiva products are truly innovative, designed with the latest understanding of materials sciences, surface technology, and physiology. This is a transformative technology that is going to disrupt the market. I am excited about working with plastic surgeons globally on Motiva, and also about bringing these new technologies and implants to the community of plastic surgeons and patients in the United States.”

Dr. Spear concluded, “I believe that the safety profile of the Generation 3 Motiva implant is superior to any other breast implant on the market today and that our continued innovation will change how both doctors and women think about implants and improve the health of women worldwide.”

Rudy Mazzocchi, Executive Chairman of Establishment Labs added, "The support of distinguished medical leaders such as Dr. Spear is a testament to the importance of what Establishment Labs is accomplishing with innovations that improve the health and safety standards for women around the world.”

Establishment Labs is currently building a second, state of the art manufacturing facility to support increased demand for its products and the beginning of the approval process in the United States for its innovative line of Motiva silicone breast implants in 2016.

Establishment Labs Announces the Appointment of Lisa Colleran, Ed Schutter and Allan Weinstein to its Board of Directors

“Lisa, Ed, and Allan bring a wealth of knowledge and experience to Establishment Labs that will complement our current Board and Management team,” said Juan Jose Chacon Quiros, CEO of Establishment Labs. “Their unique combination of skills and talents will help us achieve our goal of becoming the market leader in breast implants, both in innovation and best of class products.”

"With an unparalleled focus on the unmet needs of women around the world, and a systematic approach to product design, Establishment Labs has developed a transformative technology in the field of breast implants. I am very excited to be a part of this extraordinary Board of Directors,” said Lisa Colleran. Ms. Colleran served as President of LifeCell Corporation between 2008 and 2013, and led sell side activities for two major transactions of LifeCell, including the acquisition by KCI for $1.7 billion.

Ed Schutter is a thirty-year veteran of the pharmaceutical industry, currently the President and CEO of Arbor Pharmaceuticals. Prior to Arbor, Ed served as President of Sciele Pharmaceuticals which was sold to Shionogi & Co. Ltd. in 2008 for $1.3 billion. Of his appointment to the board, Ed Schutter said, “Establishment Labs is bringing innovation to an industry in great need of a new approach. With the best medical and scientific minds of 2015, I am confident we can create better products and solutions than the state-of-the-art from the 1990s. I am excited to be both an Investor and a Board Member of a company that can make such an impact.”

Dr. Weinstein is an independent entrepreneur focused on intellectual property in the life sciences, as well as a Board-certified immunologist and, like both Mr. Schutter and Ms. Colleran, creates a true multidisciplinary approach to building a world-class organization. Dr. Weinstein commented, “Establishment Labs brings together a world-renowned team committed to innovation and excellence. I’m pleased to join its Board of Directors, as physicians worldwide recognize the distinction of Motiva products and services in this critical field.”

Establishment Labs Announces M.I.T. Professor Dr. Robert Langer is Joining Scientific Advisory Board

Establishment Labs announced today that M.I.T. Professor Dr. Robert Langer, winner of the prestigious Lemelson-M.I.T. Innovation Prize, will join its Scientific Advisory Board.
“Our company is delighted to welcome Dr. Langer to our innovation team,” said Juan Jose Chacon Quiros, CEO of Establishment Labs. “We take women’s health in breast aesthetics and reconstruction very seriously. As we work to transform this industry we need scientists of the caliber of Dr. Langer; their minds and experience will make the difference for women worldwide.”

Dr. Langer served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 - 2002 and as its Chairman from 1999 - 2002 and has received over 220 major awards, including the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, the 2013 Wolf Prize in Chemistry, the 2014 Breakthrough Prize in Life Sciences and the 2014 Kyoto Prize. He is also the only engineer to receive the Gairdner Foundation International Award; 82 recipients of this award have subsequently received a Nobel Prize.

In 1989, Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences, and in 2012 he was elected to the National Academy of Inventors.
“There has simply been no true innovation in breast implant technology over the last 25 years and finally, Establishment Labs is a company creating real change in the industry,” said Dr. Langer. “Nanotechnology and sensor diagnostics are transforming medicine and I am enthusiastic to join the pioneering efforts of Establishment Labs in bringing this approach to breast implants.”

“Having the ability to attract the best scientists, researchers and clinicians throughout the world, further validates this company’s technological prowess in an industry that has long been underserved,” expressed Rudy Mazzocchi, Executive Chairman of Establishment Labs. “We are extremely excited to have Dr. Langer as a key member of our Scientific Advisory Board as we continue to advance our aggressive product development initiatives and build our intellectual property portfolio.”

Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the top 15 worldwide innovators who will help reinvent the future of medical implantable devices. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best).